| Q2 & H1 FY26 Earnings Conference Call
Summary : SMS Pharma delivered strong Q2/H1 FY26 results, driven by strategic backward integration and R&D, with significant capex planned for future growth despite competitive pressures.
Management Perspective positive : "I'm happy to share that we've delivered another strong quarter.""Our PAT grew 80% year-on-year to INR25.3 crores, the highest ever.""We are confident of achieving our FY '26 targets of around 20% growth.""We enter the second half of FY '26 with a strong momentum."
Concall Report Analysis & Insights
Business Overview
- Q2 FY26 PAT grew 80% year-on-year to INR25.3 crores, highest ever.
- Achieved strong revenue growth and margin expansion.
- Performance driven by product mix optimization and backward integration.
- H1 FY26 revenue from operations reached INR438.4 crores, 21% YOY growth.
- Q2 EBITDA stood at INR48.3 crores, up 54% YOY, with 20% margin.
Future Growth Prospects
- Invested INR150 crores in backward integration for critical intermediates.
- INR280 crores new capex program on track for completion by Nov 2026.
- Capex will enhance existing API capacities and build new product pipeline.
- R&D strength to double over next 2 years, targeting 30 more DMF filings.
- Peptide initiatives with commercial operations targeted for FY '29.
Management Insights
- Delivered a strong quarter with record PAT, revenue growth, and margin expansion.
- Backward integration is central to long-term strategy, improving cost and reliability.
- R&D has delivered strong outcomes, leading to successful product launches.
- Confident in achieving FY '26 targets of 20% growth and 20% EBITDA margin.
- Growth driven by backward integration, R&D, plant engineering, and diversified portfolio.
Signs of Skepticism
- Anti-diabetic segment growth has slowed due to increased competition.
- Analyst noted high receivable days and working capital, seeking improvement plans.
- Ibuprofen production currently at 350 tons/month, below 450 tons/month target.
Good To Know
- Backward integration reduces dependency on external suppliers, especially China.
- Joint venture with Chemo for first-to-market APIs in Europe.
- Largest therapeutic category (Anti-diabetic) accounts for 24% of revenue.
- Net asset turnover of 1.5x, among the best in the industry.
Key Drivers
- Backward integration improves cost competitiveness.
- New capex expands capacity for growth.
- Strong R&D pipeline drives new products.
- Diversified portfolio reduces single product risk.
Key Analyst Discussions
Competitive Environment
- Questions on SMS Pharma's competitive edge against new API/CRAMS players.
- Inquiry about market share consolidation in the Anti-diabetic segment.
Financial Highlights
- Questions on capex progress, cash spent, and expected revenue/EBITDA contribution.
- Inquiries about margin improvements and cost planning strategies.
- Concerns regarding high receivable days and working capital cycle.
Product Composition
- Questions about Ibuprofen API production targets and current run rate.
- Inquiry about growth prospects for the ARV category.
- Discussion on the Anti-diabetic portfolio's slowed growth and future.
Strategic Considerations
- Questions on customer concentration and order visibility for H2 FY26.
- Inquiry about further room for gross margin improvement from backward integration.